Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM61JH5)

Drug Name

BIWA 4 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Extracellular matrix receptor III (CD44)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
A-6	DM6ZIES	Macular degeneration	9B78.3	Phase 2	[3]
SPL-108	DMRXCUQ	Ovarian cancer	2C73	Phase 2	[4]
Bivatuzumab mertansine	DM0DO4S	Solid tumour/cancer	2A00-2F9Z	Terminated	[2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Extracellular matrix receptor III (CD44)	TTWFBT7	CD44_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02204046) Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast. U.S. National Institutes of Health.
2	A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72.
3	Modulation of CD44 Activity by A6-Peptide.Front Immunol.2015 Mar 30;6:135.
4	Clinical pipeline report, company report or official report of Splash Pharmaceuticals.